

Table S3 - Association between leukocyte subsets and sural sensory nerve action potential (SNAP) amplitude

	Model 1			Model 2			Model 3		
	β	95% CI	<i>P</i>	β	95% CI	<i>P</i>	β	95% CI	<i>P</i>
Monocytes	0.050	(-0.196; 0.297)	0.690	0.031	(-0.216; 0.280)	0.801	0.039	(-0.210; 0.289)	0.756
Basophils	0.106	(-0.812; 1.024)	0.820	0.043	(-0.879; 0.966)	0.926	0.192	(-0.752; 1.138)	0.689
Eosinophils	-0.099	(-0.353; 0.153)	0.439	-0.097	(-0.351; 0.155)	0.448	-0.082	(-0.337; 0.173)	0.527
Neutrophils	0.021	(-0.039; 0.082)	0.483	0.026	(-0.035; 0.087)	0.402	0.003	(-0.059; 0.067)	0.905
Lymphocytes	-0.026	(-0.092; 0.039)	0.424	-0.030	(-0.096; 0.035)	0.363	-0.007	(-0.075; 0.061)	0.832
T cells	-0.016	(-0.073; 0.041)	0.577	-0.015	(-0.073; 0.041)	0.585	-0.023	(-0.081; 0.034)	0.433
CD4⁺ T cells	0.008	(-0.034; 0.052)	0.690	0.014	(-0.029; 0.058)	0.517	0.015	(-0.029; 0.059)	0.506
CD8⁺ T cells	-0.007	(-0.055; 0.041)	0.767	-0.014	(-0.062; 0.034)	0.571	-0.012	(-0.061; 0.036)	0.616
T reg cells	0.140	(-0.118; 0.400)	0.286	0.130	(-0.129; 0.390)	0.325	0.085	(-0.180; 0.350)	0.528
B cells	0.004	(-0.103; 0.111)	0.938	0.002	(-0.104; 0.110)	0.959	0.005	(-0.102; 0.114)	0.919

Model 1: adjusted for sex and age.

Model 2: adjusted for model 1+ glucose metabolism status.

Model 3: adjusted for model 2 + BMI, HbA1c, total cholesterol, triglycerides, eGFR, hypertension, history of CVD, glucose-lowering drugs, lipid-lowering drugs, nonsteroidal anti-inflammatory drugs, smoking and alcohol consumption.

CI, confidence interval